Guidance A-Z — B
115 guidance documents beginning with B.
Babies, children and young people's experience of healthcare
Bair Hugger for measuring core temperature during perioperative care
Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis
Balloon catheter insertion for Bartholin's cyst or abscess
Balloon cryoablation for Barrett's oesophagus
Balloon cryoablation for squamous dysplasia of the oesophagus
Balloon dilation for chronic eustachian tube dysfunction
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour
Balloon kyphoplasty for vertebral compression fractures
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal)
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)
Baricitinib for moderate to severe rheumatoid arthritis
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)
Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib for treating severe alopecia areata
Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management
BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment
Bedwetting in children and young people
Bedwetting in under 19s
Behaviour change: digital and mobile health interventions
Behaviour change: general approaches
Behaviour change: individual approaches
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Belimumab for treating lupus nephritis (terminated appraisal)
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over
Belzutifan for treating tumours associated with von Hippel-Lindau disease
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
Benralizumab for treating severe eosinophilic asthma
Berotralstat for preventing recurrent attacks of hereditary angioedema
Beta interferons and glatiramer acetate for treating multiple sclerosis
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Bevacizumab gamma for treating wet age-related macular degeneration
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis
Bimekizumab for treating active psoriatic arthritis
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)
Bimekizumab for treating moderate to severe plaque psoriasis
Bindex for investigating suspected osteoporosis
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
Biodegradable subacromial spacer insertion for rotator cuff tears
Biomarker tests to help diagnose preterm labour in women with intact membranes
Biopatch for venous or arterial catheter sites
Bioprosthetic plug insertion for anal fistula
Bioresorbable stent implantation to treat coronary artery disease
Bipolar disorder in adults
Bipolar disorder, psychosis and schizophrenia in children and young people
Bipolar disorder: assessment and management
Birch bark extract for treating epidermolysis bullosa
Bisphosphonates for treating osteoporosis
Bladder cancer
Bladder cancer: diagnosis and management
Bladder EpiCheck for detecting bladder cancer recurrence
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
Blood transfusion
Blood transfusion
Borderline personality disorder: recognition and management
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib for previously untreated mantle cell lymphoma
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Bortezomib monotherapy for relapsed multiple myeloma
Boston Keratoprosthesis Type I for corneal blindness
Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision
Brain tumours (primary) and brain metastases in over 16s
Brain tumours (primary) and brain metastases in over 16s
Breast cancer
Breast reconstruction using lipomodelling after breast cancer treatment
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
Bair Hugger for measuring core temperature during perioperative care
Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis
Balloon catheter insertion for Bartholin's cyst or abscess
Balloon cryoablation for Barrett's oesophagus
Balloon cryoablation for squamous dysplasia of the oesophagus
Balloon dilation for chronic eustachian tube dysfunction
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour
Balloon kyphoplasty for vertebral compression fractures
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal)
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)
Baricitinib for moderate to severe rheumatoid arthritis
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)
Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib for treating severe alopecia areata
Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management
BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment
Bedwetting in children and young people
Bedwetting in under 19s
Behaviour change: digital and mobile health interventions
Behaviour change: general approaches
Behaviour change: individual approaches
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Belimumab for treating lupus nephritis (terminated appraisal)
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over
Belzutifan for treating tumours associated with von Hippel-Lindau disease
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
Benralizumab for treating severe eosinophilic asthma
Berotralstat for preventing recurrent attacks of hereditary angioedema
Beta interferons and glatiramer acetate for treating multiple sclerosis
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Bevacizumab gamma for treating wet age-related macular degeneration
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis
Bimekizumab for treating active psoriatic arthritis
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)
Bimekizumab for treating moderate to severe plaque psoriasis
Bindex for investigating suspected osteoporosis
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
Biodegradable subacromial spacer insertion for rotator cuff tears
Biomarker tests to help diagnose preterm labour in women with intact membranes
Biopatch for venous or arterial catheter sites
Bioprosthetic plug insertion for anal fistula
Bioresorbable stent implantation to treat coronary artery disease
Bipolar disorder in adults
Bipolar disorder, psychosis and schizophrenia in children and young people
Bipolar disorder: assessment and management
Birch bark extract for treating epidermolysis bullosa
Bisphosphonates for treating osteoporosis
Bladder cancer
Bladder cancer: diagnosis and management
Bladder EpiCheck for detecting bladder cancer recurrence
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
Blood transfusion
Blood transfusion
Borderline personality disorder: recognition and management
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib for previously untreated mantle cell lymphoma
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Bortezomib monotherapy for relapsed multiple myeloma
Boston Keratoprosthesis Type I for corneal blindness
Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision
Brain tumours (primary) and brain metastases in over 16s
Brain tumours (primary) and brain metastases in over 16s
Breast cancer
Breast reconstruction using lipomodelling after breast cancer treatment
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
12